Document:

Public Health Service Patent License Agreement

Exhibit 10.34

PUBLIC HEALTH SERVICE

PATENT LICENSE AGREEMENT-EXCLUSIVE

COVER PAGE

For PHS internal use only:

Patent License Number:

U.S. Application Serial No. 07/492,468 filed 3/13/90; “06-Substituted Guanine
Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase Levels” Issued 2/25/92 U.S. Pat.
5,091,430

U.S. Application Serial No. 07/616,913 filed 11/21/90; “06-Benzylated Guanine,
Guanosine and 2’-Deoxyguanosine Compounds Possessing 06-Alkylguanine-DNA Alkyltransferase Depleting Activity” CIP of
‘468 issued 10/4/94 U.S. Pat. 5,352,669

U.S. Application Serial No. 07/805,634 filed 12/21/91; “06-Substituted Guanine
Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase Levels” DIV of ‘468, issued 10/25/94 U.S. Pat.
5,358,952

U.S. Application Serial No. 07/875,438 filed 4/29/92; “06-Substituted Guanine
Compounds and Methods for Depleting Derivatives 06 Alkylguanine-DNA Alkyltransferase Levels” CIP of ‘634 Abandoned
8/19/94

U.S. Application Serial No. 08/255,190 filed 6/7/94; “06-Substituted Guanine
Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase” CIP of ‘438, and ‘913 issued 11/25/97
U.S. Pat. 5691,307.

U.S. Application Serial No. 08/283,953 filed 8/1/94; “Substituted 06-Benzylguanines
And 6(4)-Benzyloxpyrimidines” issued 6/11/96 U.S. Pat. 5,525,606, and PCT/US95/09702 filed 7/31/95 (based on parent
application 08/283.953.  National Stage filed in Europe (EPO Application No. 9592837.7.  Validated in all countries,
except Finland, under the European Patent Convention), Canada (Canadian Application No. 2,195,856), Japan (Japanese Application No.
506694/1996), Australia (Australian Serial No. 32079/95, Issued Patent No. 702711) and U.S. Application No. 08/849,223, Issued
9/28/99 as U.S. Patent No. 5,958,932).   Divisional of EP ‘837.7, Application No. 01108585.9 filed 4/5/01.

U.S. Application Serial No. 08/661,923 filed 6/11/96, issued 5/19/98 as 5,753,668;
“Substituted Benzyloxpyrimidines and Their Inactivation of 06-Alkylguanine-DNA Alkyltransferase” DIV of parent
application 08/283.953.

U.S. Application Serial No. 08/927, 846 filed 9/11/97.  Issued 6/29/99 as 5,916,894;
“Substituted 06-Benzylguanines And 6(4) - Benzyloxpyrimidines” DIV of parent application 08/283,953.

U.S. Application Serial No. 08/318,238 filed 5/25/99.  Issued 1/9/01 as 6,172,070;
“Substituted 06-Benzylguanines And 6(4) - Benzyloxpyrimidines” DIV of parent application 08/283.953.

U.S. Application Serial No. 08/849,223 filed 7/31/95.  Issued 9/28/99 as 5,958,932;
“Substituted 06-Benzylguanines And 6(4) - Benzyloxpyrimidines” CIP of parent application 08/283,953.

U.S. Application No. 09/590,187, filed 6/9/00, U.S. Patent 6,303,604, issued 10/16/0l U.S.
Application Serial No. 09/333,047 filed 6/15/99 (Allowed) “Pharmaceutical Composition Comprising
2,4-Diamino-6-Benzyloxy-Triazine And Inactivation of 06-Alkylguanine-DNA-Alkyltransferase.”

U.S. Application No. 09/333,047, filed 6/15/99, U.S. Patent 6,333,331, issued 12/25/01
“Substituted 06-Benzylguanines.”

U.S. Application No. 09/928,410; filed 8/14/01 “Substituted 06
Benzyl-B-Aza-Guanines” Pending.

Licensee:  Procept, Inc. (formerly named Pacific
Pharmaceuticals, Inc.)

Cooperative Research and Development Agreement (CRADA) Number (if applicable): 
#0303

Additional
Remarks:

PHS, by executing interinstitutional agreements between the
Milton S. Hershey Medical Center of Pennsylvania State University (L-067-02/0), and the University of Chicago (L-086-02/0), has
obtained the exclusive license to, including the right to Sublicense, the Licensed Patent Rights listed in
Appendix A.  Once executed, the terms and conditions of this Agreement shall supersede, and thereby terminate, the terms
and conditions of the previous license agreement between the Licensee and the Pennsylvania State University, made effective
on February 6, 1998

Public Benefit(s):

Procept agrees that subsequent to market approval by the Food and Drug Administration
(FDA), to make reasonable quantities of Licensed Product(s) or materials produced through the use of Licensed
Process(es) available on a compassionate use basis, to patients, either through the patient’s physicians) and/or the
medical center treating the patient; and Procept further agrees, after their First Commercial Sale, and to develop written
educational materials (e.g., brochures, advertisements, etc.) directed to patients and physicians detailing the Licensed
Product(s) and/or medical aspects of using 06-Benzylguanine and/or its derivatives as a therapeutic modality for the treatment
of human cancers.

This Patent License Agreement, hereinafter referred to as the
“Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List
of Patent(s) and/or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties),
Appendix D (Modifications), Appendix E (Benchmarks), Appendix F (Commercial Development Plan),
Appendix G (Sublicense Agreement ), Appendix H (Amendment to said Sublicense Agreement) and Appendix I
(Release Agreement and its Relevant Exhibits).  The Parties to this Agreement are:

	

1)

    	The National
Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), or the Food and Drug
Administration (“FDA”), hereinafter singly or collectively referred to as “PHS”, agencies of
the United States Public Health Service within the Department of Health and Human Services (“DHHS”);
and
	

2)

    	 Procept,
Inc., having offices at the address indicated on the Signature Page, hereinafter referred to as
“Licensee”.

 

PHS PATENT LICENSE AGREEMENT-EXCLUSIVE

PHS and Licensee agree as follows:

	
    l.	
BACKGROUND
	
     	1.01	In the course of fundamental research
programs at the PHS, Robert C. Moschel (PHS), Anthony Pegg (Milton S. Hershey Medical Center of Pennsylvania State
University, (PSU)), and Eileen Dolan (Milton S. Hershey Medical of Pennsylvania State University Center and the University
of Chicago (UC), whereas UC, under an agreement with its affiliated corporation, ARCH Development Corporation has the
right to license Licensed Patents and other intellectual property owned by ARCH ), made or reduced to practice certain inventions
which are included within the Licensed Patent Rights, as defined in Paragraph 2.06 below.
	
     	
    1.02	 PHS, by executing
interinstitutional agreements with PSU (L-067-02/0), and UC (L-086-02/0), has obtained the exclusive license,
including the right to sublicense, the Licensed Patent Rights listed in Appendix A.  Once executed, the terms and
conditions of this Agreement shall supersede, and thereby terminate the terms and conditions of the previous license
agreement between Pacific Pharmaceuticals, Inc. (now Procept, Inc.) and PSU, made effective on February 6, 1998,
provided that, the sublicense agreement, including its associated amendment, by and between AOI Pharmaceuticals, Inc.
(“Sublicensee”) and Licensee made effective on October 13, 2000, and attached as Appendices G and H (such
sublicense agreement and its associated amendment, the “Sublicensee Agreement”), shall continue to remain in
full force and effect.
	
     	1.03	By assignment of rights from
PHS employees and other inventors, DHHS, on behalf of the United States Government, owns intellectual property
rights claimed in any United States and/or foreign patent applications or patents corresponding to the assigned inventions. 
DHHS also owns any tangible embodiments of these inventions actually reduced to practice by PHS.
	 	1.04	 The Secretary of DHHS has
delegated to PHS the authority to enter into this Agreement for the licensing of rights to these
inventions.
	
     	1.05	 PHS desires to transfer these
inventions to the private sector through commercialization licenses to facilitate the commercial development of products and
processes for public use and benefit.
	
     	1.06	 Licensee desires to acquire
commercialization rights to certain of these inventions in order to develop processes, methods, and/or marketable products for
public use and benefit.
	
    2.	 DEFINITIONS
	
     	
    2.01 	
    “Affiliate” means,
with respect to any organization that can exercise independent legal standing, including a corporation, association, joint venture,
partnership, trust, university, business, individual, government or political subdivision thereof (any such organization, an
“Entity”), any Entity that directly or indirectly controls, is controlled by, or is under common control
with such Entity.  “Control” for this purpose shall mean control of more than fifty percent (50%) of the
voting securities of an Entity.
	
     	
    2.02	
    “Benchmarks” mean
the performance milestones that are set forth in Appendix E.

 

	 	
    2.03	“Commercial Development
Plan” means the written commercialization plan attached as Appendix F.
	 	
    2.04 	“First Commercial
Sale” means the initial transfer by or on behalf of Licensee or its sublicensees of Licensed Products or
the initial practice of a Licensed Process by or on behalf of Licensee or its sublicensees in exchange for cash or
some equivalent to which value can be assigned for the purpose of determining Net Sales.
	 	
    2.05 	“Government” means
the Government of the United States of America.
	 	
    2.06	“Licensed Fields of
Use” means the fields of use identified in Appendix B.
	 	
    2.07	“Licensed Patent
Rights” shall mean:	

Patent
applications (including provisional patent applications and PCT patent
applications) and/or patents listed in Appendix A, all divisions and
continuations of these applications, all patents issuing from such applications,
divisions, and continuations, and any reissues, reexaminations, and extensions
of all such patents;

      
	

to the extent that
the following contain one or more claims directed to the invention or inventions disclosed in a) above:  i)
continuations-in-part of a) above; ii) all divisions and continuations of these continuations-in-part; iii) all patents issuing
from such continuations-in-part, divisions, and continuations; iv) priority patent applications) of a) above; and v) any reissues,
reexaminations, and extensions of alt such patents;

      
	

to the extent
that the following contain one or more claims directed to the invention or
inventions disclosed in a) above:  all counterpart foreign and U.S. patent
applications and patents to a) and b) above, including those listed in
Appendix A.

      

 Licensed
Patent Rights shall not include b) or c) above to the extent that they contain one or more claims directed
to new matter which is not the subject matter disclosed in a) above.

    
	 	
     2.08	“Licensed
Process(es)” means processes which, in the course of being practiced would be within the scope of one or more claims of
the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable
judgment of a court of competent jurisdiction.
	 	
     2.09	“Licensed
Product(s)” means tangible materials which, in the course of manufacture, use, sale, or importation would be within the
scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by
an unappealed or unappealable judgment of a court of competent jurisdiction.
	 	
     2.10 
    	“Licensed
Territory” means the geographical area identified in Appendix B.
	 	
     2.11	“Net Sales” means
the total gross receipts actually received for sales of Licensed Products or practice of Licensed Processes by
Licensee, any of its Affiliates, its Sublicensee or any other sublicensee(s), and from leasing, renting, or otherwise
making Licensed Products available to others without sale or other dispositions, whether invoiced or not, less returns and
allowances, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately
invoiced), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted.  No deductions
shall be made for commissions paid to individuals, whether they be with independent sales agencies or regularly employed by
Licensee, Sublicensee or sublicensee(s), and on its payroll, or for the cost of collections.

 

    	 	
     2.12	“Practical
Application” means to manufacture in the case of a composition or product, to practice in the case of a process or
method, or to operate in the case of a machine or system; and in each case, under such conditions as to establish that the
invention is being utilized and that its benefits are to the extent permitted by law or Government regulations available to
the public on reasonable terms.

    	 	
    2.13	“Research License”
means a nontransferable, nonexclusive license to make and to use the Licensed Products or Licensed Processes as
defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or
distribution or in lieu of purchase.

    	
    
    3.	
     GRANT OF
RIGHTS

    	 	
    3.01	 PHS hereby grants and
Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed
Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to
sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any
Licensed Processes in the Licensed Fields of Use.

    	 	
    3.02	This Agreement confers no license or
rights by implication, estoppel, or otherwise under any patent applications or patents of PHS other than Licensed Patent
Rights regardless of whether such patents are dominant or subordinate to Licensed Patent Rights.

    	4.	
SUBLICENSING

    	 	
    4.01	Upon written approval by PHS,
Licensee and Sublicensee may enter into sublicensing agreements under the Licensed Patent Rights. 
Notwithstanding anything else stated herein, PHS acknowledges that this Agreement does not terminate, alter or
supersede the Sublicensee Agreement that existed and continues to exist between Licensee and Sublicensee, and
listed in Appendices G and H respectively, pursuant to Section 1.02 of this Agreement.  PHS hereby approves the
Sublicensee Agreement in the event of termination of this Agreement under Article 13.

    	 	
    4.02	 Licensee agrees that any
sublicenses granted by it shall provide that the obligations to PHS of Paragraphs 5.0l-5.04, 8.01, 9.02, 10.01, 10.02,
12.05, and 13.07-13.09 of this Agreement shall be binding upon the sublicensee(s) as if it were a party to this
Agreement.  Licensee further agrees to attach copies of these Paragraphs to all sublicense
agreements.

    	 	
    4.03	Any sublicenses granted by
Licensee shall provide for the termination of the sublicense or the conversion to a license directly between such
sublicensee(s) and PHS, at the option of the Sublicensee, upon termination of this Agreement under Article 13,
and shall be under substantially similar terms of this Agreement, wherein all considerations are in cash.  Such
conversion is subject to PHS approval and contingent upon acceptance by the Sublicensee of the remaining provisions
of this Agreement.

    	 	
    4.04	 Licensee agrees to forward to
PHS a copy of each fully executed sublicense agreement postmarked within thirty (30) days of the execution of such
agreement.  To the extent permitted by law, PHS agrees to maintain each such sublicense agreement in
confidence.

 

	
    
    5.	
     STATUTORY AND PHS REQUIREMENTS AND
    RESERVED GOVERNMENT RIGHTS

    	 	
    
    5.01	
    (a)	 PHS reserves on behalf of the Government an
irrevocable, nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under the Licensed
Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or
international organization pursuant to any existing or future treaty or agreement to which the Government is a
signatory.  Prior to the First Commercial Sale, Licensee agrees to provide PHS reasonable quantities of
Licensed Products or materials made through the Licensed Processes for PHS research use.

    	 	 	
    (b)	In the event that
Licensed Patent Rights are Subject Inventions made under a Cooperative Research and Development Agreement (CRADA),
Licensee grants to the Government, pursuant to 15 U.S.C. 3710a(b)(1)(A), a nonexclusive, nontransferable,
irrevocable, paid-up license to practice Licensed Patent Rights or have Licensed Patent Rights practiced throughout
the world by or on behalf of the Government.  In the exercise of such license, the Government shall not publicly
disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C.
552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party.  Prior to the First
Commercial Sale, Licensee agrees to provide PHS reasonable quantities of Licensed Products or materials
made through the Licensed Processes for PHS research use.

    	 	
    5.02	 Licensee agrees that products
used or sold in the United States embodying Licensed Products or produced through use of Licensed Processes shall be
manufactured substantially in the United States, unless a written waiver is obtained in advance from PHS.
	 	
    5.03	 Licensee acknowledges that
PHS may enter into future Cooperative Research and Development Agreements (CRADAs) under the Federal Technology
Transfer Act of 1986 that relate to the subject matter of this Agreement.  Licensee agrees not to unreasonably
deny requests for a Research License from such future collaborators with PHS when acquiring such rights is necessary
in order to make a Cooperative Research and Development Agreement (CRADA) project feasible.  Licensee may
request an opportunity to join as a party to the proposed Cooperative Research and Development Agreement (CRADA).
	 	
    5.04	
    (a)	 In addition to the reserved license of Paragraph 5.01 above,
PHS reserves the right to grant nonexclusive Research Licenses directly or to require Licensee to grant
nonexclusive Research Licenses on reasonable terms.  The purpose of this Research License is to encourage basic
research, whether conducted at an academic or corporate facility.  In order to safeguard the Licensed Patent Rights,
however, PHS shall consult with Licensee before granting to commercial entities a Research License or
providing to them research samples of materials made through the Licensed Processes.
	 	
     	
    (b)	In exceptional
circumstances, and in the event that Licensed Patent Rights are Subject Inventions made under a Cooperative Research and
Development Agreement (CRADA), the Government, pursuant to 15 U.S.C. 3710a(b)(1)(B), retains the right to require the
Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use Licensed
Patent Rights in Licensee’s field of use on terms that are reasonable under the circumstances; or if
Licensee fails to grant such a license, the Government retains the right to grant the license itself.  The
exercise of such rights by the Government shall only be in exceptional circumstances and only if the Government
determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Licensee; (ii)
the action is necessary to meet requirements for public use specified by Federal regulations, and such requirements are not
reasonably satisfied by the Licensee; or (iii) the Licensee has failed to comply with an agreement containing
provisions described in 15 U.S.C. 3710a(c)(4)(B).  The determination made by the Government under this Article is
subject to administrative appeal and judicial review under 35 U.S.C. 203(2).

 

    	
    6.	 ROYALTIES
AND REIMBURSEMENT

    	 	
    6.01	 Licensee agrees to pay to
PHS a noncreditable, nonrefundable license issue royalty as set forth in Appendix C within thirty (30) days from the
date that this Agreement becomes effective.
	
     	
    6.02	 Licensee agrees to pay to
PHS a nonrefundable minimum annual royalty as set forth in Appendix C.  The minimum annual royalty is due and
payable on January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year. 
The minimum annual royalty due for the first calendar year of this Agreement may be prorated according to the fraction of
the calendar year remaining between the effective date of this Agreement and the next subsequent January 1.
	
     	
    6.03.	 Licensee agrees to pay
PHS earned royalties as set forth in Appendix C.
	
     	
    6.04	 Licensee agrees to pay
PHS benchmark royalties as set forth in Appendix C.
	
     	
    6.05	 Licensee agrees to pay
PHS sublicensing royalties as set forth in Appendix C.
	
     	
    6.06	A patent or patent application
licensed under this Agreement shall cease to fall within the Licensed Patent Rights for the purpose of computing
earned royalty payments in any given country on the earliest of the dates that a) the application has been abandoned and not
continued, b) the patent expires or irrevocably lapses, or c) the claim has been held to be invalid or unenforceable by an
unappealed or unappealable decision of a court of competent jurisdiction or administrative agency.
	
     	
    6.07	No multiple royalties shall be
payable because any Licensed Products or Licensed Processes are covered by more than one of the Licensed Patent
Rights.
	
     	
    6.08	On sales of Licensed Products
by Licensee or on sales made in other than an arm’s-length transaction, the value of the Net Sales attributed
under this Article 6 to such a transaction shall be that which would have been received in an arm’s-length transaction, based
on sales of like quantity and quality products on or about the time of such transaction.
	
     	
    6.09	With regard to expenses associated
with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the Licensed
Patent Rights incurred by PHS prior to the effective date of this Agreement, Licensee shall pay to
PHS, as an additional royalty, within sixty (60) days of PHS’s submission of a statement and request for
payment to Licensee, an amount equivalent to such patent expenses previously incurred by PHS unless such expenses are
disputed in good faith by Licensee, in which case the parties will attempt to resolve amicably the dispute pursuant to
paragraph 14.12.
	
     	
    6.10	With regard to expenses associated
with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the Licensed
Patent Rights incurred by PHS on or after the effective date of this Agreement, PHS, at its sole option,
may require Licensee:
	
     	
    	
    

 

	
     	
     	
     (a)	to pay PHS on an
annual basis, within sixty (60) days of PHS’s submission of a statement and request for payment, a royalty amount
equivalent to all such patent expenses incurred during the previous calendar year(s); or
	
     	
     	
     (b)	to pay such expenses
directly to the law firm employed by PHS to handle such functions.  However, in such event, PHS and not
Licensee shall be the client of such law firm.
	
     	 
    	In limited circumstances, Licensee may be given the right to assume responsibility for the preparation, filing, prosecution,
or maintenance of any patent application or patent included with the Licensed Patent Rights.  In that event,
Licensee shall directly pay the attorneys or agents engaged to prepare, file, prosecute, or maintain such patent
applications or patents and shall provide to PHS copies of each invoice associated with such services as well as
documentation that such invoices have been paid.
	
     	
    6.11	 Licensee may elect to
surrender its rights in any country of the Licensed Territory under any Licensed Patent Rights upon ninety (90) days
written notice to PHS and owe no payment obligation under Article 6.10 for patent-related expenses incurred in that country
after ninety (90) days of the effective date of such written notice.
	
     7.	 PATENT
FILING, PROSECUTION, AND MAINTENANCE
	
     	
    7.01 	Except as otherwise provided in this
Article 7, PHS agrees to take responsibility for, but to consult with, the Licensee in the preparation, filing,
prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall
furnish copies of relevant patent-related documents to Licensee.
	
     	
    7.02	Upon PHS’s written
request, Licensee shall assume the responsibility for the preparation, filing, prosecution, and maintenance of any and all
patent applications or patents included in the Licensed Patent Rights and shall on an ongoing basis promptly furnish copies
of all patent-related documents to PHS.  In such event, Licensee shall, subject to the prior approval of
PHS, select registered patent attorneys or patent agents to provide such services on behalf of Licensee and
PHS.  PHS shall provide appropriate powers of attorney and other documents necessary to undertake such actions
to the patent attorneys or patent agents providing such services.  Licensee and its attorneys or agents shall consult
with PHS in all aspects of the preparation, filing, prosecution and maintenance of patent applications and patents included
within the Licensed Patent Rights and shall provide PHS sufficient opportunity to comment on any document that
Licensee intends to file or to cause to be filed with the relevant intellectual property or patent office.
	
     	
    7.03 	At any time, PHS may provide
Licensee with written notice that PHS wishes to assume control of the preparation, filing, prosecution, and
maintenance of any and all patent applications or patents included in the Licensed Patent Rights.  If PHS elects
to assume such responsibilities, Licensee agrees to cooperate fully with PHS, its attorneys, and agents in the
preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent
Rights and to provide PHS with complete copies of any and all documents or other materials that PHS deems
necessary to undertake such responsibilities.  Licensee shall be responsible for all costs associated with transferring
patent prosecution responsibilities to an attorney or agent of PHS’s choice.
	
     	
    7.04	Each party shall promptly inform the
other as to all matters that come to its attention that may affect the preparation, filing, prosecution, or maintenance of the
Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing,
prosecution, and maintenance of Licensed Patent Rights, which comments and suggestions shall be considered by the other
party.

 

	
     8.	
RECORDKEEPING
	
     	
    8.01	 Licensee agrees to keep
accurate and correct records of Licensed Products made, used, sold, or imported and Licensed Processes practiced
under this Agreement appropriate to determine the amount of royalties due PHS.  Such records shall be retained
for at least five (5) years following a given reporting period and shall be available during normal business hours, and upon
reasonable written notice for inspection at the expense of PHS, by an accountant or other designated auditor selected by
PHS for the sole purpose of verifying reports and payments hereunder.  The accountant or auditor shall only disclose to
PHS information relating to the accuracy of reports and payments made under this Agreement.  If an inspection
shows an underreporting or underpayment in excess of five percent (5%)for any twelve (12) month period, then Licensee shall
reimburse PHS for the cost of the inspection at the time Licensee pays the unreported royalties, including any late
charges as required by Paragraph 9.08 of this Agreement.  All payments required under this Paragraph shall be due
within thirty (30) days of the date PHS provides Licensee notice of the payment due.
	
     	 8.02	 Licensee agrees to have an
audit of sales and royalties conducted by an independent auditor at least every two (2) years if annual sales of the Licensed
Product or Licensed Processes are over two (2) million dollars.  The audit shall address, at a minimum, the amount
of gross sales by or on behalf of Licensee during the audit period, terms of the license as to percentage or fixed royalty
to be remitted to the Government, the amount of royalty funds owed to the Government under this Agreement, and
whether the royalty amount owed has been paid to the Government and is reflected in the records of the
Licensee.  The audit shall also indicate the PHS license number, product, and the time period being
audited.  A report certified by the auditor shall be submitted promptly by the auditor directly to PHS on
completion.  Licensee shall pay for the entire cost of the audit.
	
     9.	 REPORTS ON
PROGRESS, BENCHMARKS, SALES, AND PAYMENTS
	
     	
    9.01 	Prior to signing this
Agreement, Licensee has provided to PHS the Commercial Development Plan at Appendix F, under which
Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical
Application.  This Commercial Development Plan is hereby incorporated by reference into this
Agreement.  Based on this plan, performance Benchmarks are determined as specified in
Appendix E.
	
     	
    9.02	 Licensee shall provide written
annual reports on its product development progress or efforts to commercialize under the Commercial Development Plan for
each of the Licensed Fields of Use within sixty (60) days after December 31 of each calendar year.  These progress
reports shall include, but not be limited to:  progress on research and development, status of applications for regulatory
approvals, manufacturing, sublicensing, marketing, importing, and sales during the preceding calendar year, as well as plans for
the present calendar year.  PHS also encourages these reports to include information on any of Licensee’s
public service activities that relate to the Licensed Patent Rights.  If reported progress differs from that projected
in the Commercial Development Plan and Benchmarks, Licensee shall explain the reasons for such
differences.  In any such annual report, Licensee may propose amendments to the Commercial Development Plan,
acceptance of which by PHS may not be denied unreasonably.  Licensee agrees to provide any additional
information reasonably required by PHS to evaluate Licensee’s performance under this Agreement. 
Licensee may amend the Benchmarks at any time upon written consent by PHS.  PHS shall not
unreasonably withhold approval of any request of Licensee to extend the time periods of this schedule if such request is
supported by a reasonable showing by Licensee of diligence in its performance under the Commercial Development Plan
and toward bringing the Licensed Products to the point of Practical Application as defined in 37 CFR 404.3(d). 
Licensee shall amend the Commercial Development Plan and Benchmarks at the request of PHS to address
any Licensed Fields of Use not specifically addressed in the plan originally submitted.

 

	
     	
    9.03	 Licensee shall report to
PHS the dates for achieving Benchmarks specified in Appendix E and the First Commercial Sale in each
country in the Licensed Territory within thirty (30) days of such occurrences.
	
     	
    9.04	 Licensee shall submit to
PHS within sixty (60) days after each calendar half-year ending June 30 and December 31 a royalty report setting forth for
the preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on
behalf of Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty
accordingly due.  With each such royalty report, Licensee shall submit payment of the earned royalties due.  If no
earned royalties are due to PHS fox any reporting period, the written report shall so state.  The royalty report shall
be certified as correct by an authorized officer of Licensee and shall include a detailed listing of all deductions made
under Paragraph 2.10 to determine Net Sales made under Article 6 to determine royalties due.
	
     	
    9.05	 Licensee agrees to forward
semi-annually to PHS a copy of such reports received by Licensee from its sublicensees during the preceding half-year
period as shall be pertinent to a royalty accounting to PHS by Licensee for activities under the
sublicense.
	
     	
    9.06	Royalties due under Article 6 shall
be paid in U.S. dollars.  For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York
foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due.  All checks and bank drafts
shall be drawn on United States banks and shall be payable, as appropriate, to “NIH/Patent Licensing.” All such
payments shall be sent to the following address:  NIH, P.O. Box 360120, Pittsburgh, Pennsylvania 15251-6120.  Any loss of
exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by
Licensee.  The royalty report required by Paragraph 9.04 of this Agreement shall accompany each such payment,
and a copy of such report shall also be mailed to PHS at its address for notices indicated on the Signature Page of this
Agreement.
	
     	
    9.07	 Licensee shall be solely
    responsible for determining if any tax on royalty income is owed outside the United States and shall pay any such tax and be
responsible for all filings with appropriate agencies of foreign governments.
	
     	
    9.08	 Interest and penalties may be
assessed by PHS on any overdue payments in accordance with the Federal Debt Collection Act.  The payment of such late
charges shall not prevent PHS from exercising any other rights it may have as a consequence of the lateness of any
payment.
	
     	
    9.09	
    All plans and reports required by this Article 9 and marked “confidential”
    by Licensee shall, to the extent permitted by law, be treated by
PHS as commercial and financial information obtained from a person and as
    privileged and confidential, and any proposed disclosure of such records by
    the PHS under the Freedom of Information Act (FOIA), 5 U.S.C. §552
    shall be subject to the predisclosure notification requirements of 45 CFR
    §5.65(d).
	
    10.	
PERFORMANCE
	
     	
    10.01	 Licensee shall use its reasonable best
efforts to bring the Licensed Products and Licensed Processes to Practical Application. 
“Reasonable best efforts” for the purposes of this provision shall include commercially reasonable best efforts to
adhere to the Commercial Development Plan at Appendix F and perform the Benchmarks at Appendix E.  The
efforts of a sublicensee shall be considered the efforts of Licensee.

 

	
     	
    10.02	Upon the First Commercial Sale, until the
expiration of this Agreement, Licensee shall use its reasonable best efforts to make Licensed Products and
Licensed Processes reasonably accessible to the United States public.
	
    11.	 INFRINGEMENT AND PATENT
ENFORCEMENT
	
     	
    11.01	 PHS and Licensee agree to notify
each other promptly of each infringement or possible infringement of the Licensed Patent Rights, as well as any facts which
may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either Party becomes
aware.
	
     	
    11.02 	Pursuant to this Agreement and the
provisions of Chapter 29 of title 35, United States Code, Licensee may:  a) bring suit in its own name, at its own
expense, and on its own behalf for infringement of presumably valid claims in the Licensed Patent Rights; b) in any such
suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature recoverable for such
infringement; and c) settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that
PHS and appropriate Government authorities shall have the first right to take such actions.  If Licensee
desires to initiate a suit for patent infringement, Licensee shall notify PHS in writing.  If PHS does
not notify Licensee of its intent to pursue legal action within ninety (90) days, Licensee will be free to initiate
suit.  PHS shall have a continuing right to intervene in such suit at its own expense and may consult with
Licensee in such litigation.  Licensee shall take no action to compel the Government either to initiate
or to join in any such suit for patent infringement.  Licensee may request the Government to initiate or join in
any such suit if necessary to avoid dismissal of the suit.  Should the Government be made a party to any such suit,
Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a
result of such motion or other action, including any and all costs incurred by the Government in opposing any such motion or
other action.  In all cases, Licensee agrees to keep PHS reasonably apprised of the status and progress of any
litigation.  Before Licensee commences an infringement action, Licensee shall notify PHS and give careful
consideration to the views of PHS and to any potential effects of the litigation on the public health in deciding whether to
bring suit.
	
     	
    11.03	In the event that a declaratory judgment action
alleging invalidity or non-infringement of any of the Licensed Patent Rights shall be brought against Licensee or
raised by way of counterclaim or affirmative defense in an infringement suit brought by Licensee under Paragraph 11.02,
pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code or other statutes,
Licensee may:  a) defend the suit in its own name, at its own expense, and on its own behalf for presumably valid
claims in the Licensed Patent Rights; b) in any such suit, ultimately enjoin infringement and collect for its use, damages,
profits, and awards of whatever nature recoverable for such infringement; and c) settle any claim or suit for declaratory judgment
involving the Licensed Patent Rights-provided, however, that PHS and appropriate Government authorities
shall have the first right to take such actions and shall have a continuing right to intervene in such suit.  If PHS
does not notify Licensee of its intent to respond to the legal action within a reasonable time, Licensee will be free
to do so, and PHS and any appropriate government authorities may only intervene at their own expense and may consult with
Licensee in such legal action.  Licensee shall take no action to compel the Government either to initiate
or to join in any such declaratory judgment action.  Licensee may request the Government to initiate or to join
any such suit if necessary to avoid dismissal of the suit.  Should the Government be made a party to any such suit by
motion or any other action of Licensee, Licensee shall reimburse the Government for any costs, expenses, or
fees which the Government incurs as a result of such motion or other action.  If Licensee elects not to defend
against such declaratory judgment action, PHS, at its option, may do so at its own expense.  In all cases,
Licensee agrees to keep PHS reasonably apprised of the status and progress of any litigation.  Before
Licensee commences an infringement action, Licensee shall notify PHS and give careful consideration to the
views of PHS and to any potential effects of the litigation on the public health in deciding whether to bring
suit.

 

	
     	
    11.04	In any action under Paragraphs 11.02 or 11.03,
the expenses including costs, fees, attorney fees, and disbursements, shall be paid by Licensee.  The value of any
recovery made by Licensee through court judgment or settlement shall be treated as Net Sales and subject to earned
royalties.
	
     	
    11.05 	 PHS shall cooperate fully with
Licensee in connection with any action under Paragraphs 11.02 or 11.03.  PHS agrees promptly to provide access
to all necessary documents and to render reasonable assistance in response to a request by Licensee.
	
    12.	 NEGATION OF WARRANTIES
AND INDEMNIFICATION
	
     	
    12.01	 PHS offers no warranties other than those
specified in Articles 1 and 4.01.
	
     	
    12.02 	 PHS does not warrant the validity of the
Licensed Patent Rights and makes no representations whatsoever with regard to the scope of the Licensed Patent
Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual
property rights of third parties.
	
     	
    12.03	 PHS MAKES NO WARRANTIES, EXPRESSED OR
IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED
PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO.
	
     	
    12.04	 PHS does not represent that it will
commence legal actions against third parties infringing the Licensed Patent Rights.
	
     	
    12.05	 Licensee shall indemnify and hold
PHS, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages,
expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or
arising out of a) the use by or on behalf of Licensee, its sublicensees, directors, employees, or third parties of any
Licensed Patent Rights; or b) the design, manufacture, distribution, or use of any Licensed Products, Licensed
Processes or materials by Licensee, or other products or processes developed in connection with or arising out of the
Licensed Patent Rights.  Licensee agrees to maintain a liability insurance program consistent with sound
business practice.
	
    13.	 TERM, TERMINATION, AND
MODIFICATION OF RIGHTS
	
     	
    13.01	This Agreement is effective when signed
by the Parties, except that the noncreditable, nonrefundable licensee issue royalty fee in the amount of Eighty-Five
Thousand Eight Hundred and Fifty-Eight Dollars and Fifty-Four Cents ($85,858.54 U.S. Dollars) for outstanding patent prosecution
costs owed to PHS under this Agreement will be held in escrow by Licensee until the execution of a release
agreements) by PSU and UC that is substantially similar to the Release Agreement attached hereto as
Appendix I, and shall extend to the expiration of the last to expire of the Licensed Patent Rights unless sooner
terminated as provided in this Article 13.

	
     	
    13.02	In the event that Licensee is in default
in the performance of any material obligations under this Agreement, including but not limited to the obligations listed in
Article 13.05, and if the default has not been remedied within ninety (90) days after the date on which License receives notice in
writing of such default, PHS may terminate this Agreement by written notice and pursue outstanding amounts owed
through procedures provided by the Federal Debt Collection Act.
	
     	
    13.03	 In the event tat Licensee becomes
insolvent, files a petition in bankruptcy, has such a petition filed against it, determines to file a petition in bankruptcy, or
receives notice of a third party’s intention to file an involuntary petition in bankruptcy, Licensee shall immediately
notify PHS in writing.  Furthermore, PHS shall have the right to terminate this Agreement immediately
upon Licensee’s receipt of written notice.
	
     	
    13.04 	 Licensee shall have a unilateral right to
terminate this Agreement and/or any licenses in any country or territory by giving PHS sixty (60) days written notice
to that effect.
	
     	
    13.05	 PHS shall specifically have the right to
terminate or modify, at its option, this Agreement, if PHS determines that the Licensee:  1) is not using
its commercially reasonable best efforts to execute the Commercial Development Plan submitted with its request for a license
and the Licensee cannot otherwise demonstrate to PHS’ reasonable satisfaction that the Licensee has
taken, or can be expected to take within a reasonable time, effective steps to achieve Practical Application of the
Licensed Products or Licensed Processes; 2) has not used its commercially reasonable best efforts to achieve the
Benchmarks as may be modified under Paragraph 9.02; 3) has willfully made a false statement of, or willfully omitted, a
material fact in the license application or in any report required by the license Agreement; 4) has committed a material
breach of a covenant or agreement contained in the license; 5) is not keeping Licensed Products or Licensed Processes
reasonably available to the public after commercial use commences; 6) cannot reasonably satisfy unmet health and safety needs; or
7) cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.02 unless waived.  In
making this determination, PHS will take into account the normal course of such commercial development programs conducted
with sound and reasonable business practices and judgment and the annual reports submitted by Licensee under Paragraph
9.02.  Prior to invoking this right, PHS shall give written notice to Licensee providing Licensee
specific notice of, and a ninety (90) day opportunity to respond to, PHS’ concerns as to the previous items 1) to
7).  If Licensee fails to alleviate PHS’ concerns as to the previous items 1) to 7) or fails to initiate
corrective action to PHS’ reasonable satisfaction, PHS may terminate this Agreement.
	
     	
    13.06	When the public health and safety so require,
and after written notice to Licensee providing Licensee a sixty (60) day opportunity to respond, PHS shall
have the right to require Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed
Fields of Use under the Licensed Patent Rights, unless Licensee can reasonably demonstrate that the granting of
the sublicense would not materially increase the availability to the public of the subject matter of the Licensed Patent
Rights.  PHS will not require the granting of a sublicense unless the responsible applicant has first negotiated in
good faith with Licensee.
	
     	
    13.07 	 PHS reserves the right according to 35
U.S.C. §209(f)(4) to terminate or modify this Agreement if it is determined that such action is necessary to meet
requirements for public use specified by federal regulations issued after the date of the license and such requirements are not
reasonably satisfied by Licensee.
	
     	
    13.08	Within thirty (30) days of receipt of written
notice of PHS’s unilateral decision to modify or terminate this Agreement, Licensee may, consistent with
the provisions of 37 CFR 404.11, appeal the decision by written submission to the designated PHS official.  The
decision of the designated PHS official shall be the final agency decision.  Licensee may thereafter exercise
any and all administrative or judicial remedies that may be available.

 

	
     	
    13.09	Within ninety (90) days of expiration or
termination of this Agreement under this Article 13, a final report shall be submitted by Licensee.  Any royalty
payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expense,
due to PHS shall become immediately due and payable upon termination or expiration.  If terminated under this Article
13, sublicensees may elect to convert their sublicenses to direct licenses with PHS pursuant to Paragraph 4.03.  Unless
otherwise specifically provided for under this Agreement, upon termination or expiration of this Agreement,
Licensee shall return all Licensed Products or other materials included within the Licensed Patent Rights to
PHS or provide PHS with certification of the destruction thereof.
	
    14.	 GENERAL
PROVISIONS
	
     	
    14.01	Neither Party may waive or release any of
its rights or interests in this Agreement except in writing.  The failure of the Government to assert a right
hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that
right by the Government or excuse a similar subsequent failure to perform any such term or condition by
Licensee.
	
     	
    14.02 	This Agreement constitutes the entire agreement
between the Parties relating to the subject matter of the Licensed Patent Rights, and all prior negotiations,
representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this
Agreement.  It is the mutual desire of the Licensee and the PHS that the terms of this Agreement,
shall become effective according to the conditions set forth in Section 13, and once executed, shall supersede, and thereby
terminate the terms and conditions of the following listed agreements, but not the Sublicense Agreement,
including:	

The
exclusive license agreement between the Licensee and PSU, executed February 6, 1998;

      
	

The Interinstitutional agreement between PHS and PSU (L-094-91/0), executed on May 20, 1997, but not its replacement
agreements between PHS and PSU executed January 29, 2002; and L-086-02/0 between PHS and UC executed
January 30, 2002;

      
	

The agreement between
PSU and the UC, executed on May I6, 1997.

      

    
	
     	
     	 PHS acknowledges the Release Agreement listed as Appendix I and its relevant Exhibits, of
this Agreement, entered into by and among the Licensee, the Sublicensee, PSU, UC and
PHS.
	
     	
    14.03	The provisions of this Agreement are
severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under
any controlling body of law, such determination shall not in any way affect the validity or enforceability of the remaining
provisions of this Agreement.
	
     	
    14.04	If either Party desires a modification to
this Agreement, the Parties shall, upon reasonable notice of the proposed modification by the Party desiring
the change, confer in good faith to determine the desirability of such modification.  No modification will be effective until
a written amendment is signed by the signatories to this Agreement or their designees.

 

	
     	
    14.05	The construction, validity, performance, and
effect of this Agreement shall be governed by Federal law as applied by the Federal courts in the District of
Columbia.
	
     	
    14.06 	All notices required or permitted by this
Agreement shall be given by prepaid, first class, registered or certified mail or by an express/overnight delivery service
provided by a commercial carrier, properly addressed to the other Party at the address designated on the following Signature
Page, or to such other address as may be designated in writing by such other Party.  Notices shall be considered timely
if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by
U.S. Postal Service postmark or dated receipt from a commercial carrier.  Parties should request a legibly dated U.S.
Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service.  Private metered
postmarks shall not be acceptable as proof of timely mailing.
	
     	
    14.07 	This Agreement shall not be assigned by
Licensee except:  a) with the prior written consent of PHS, such consent not to be withheld unreasonably; or b)
as part of a sale or transfer of substantially the entire business of Licensee relating to operations which concern this
Agreement.  Licensee shall notify PHS within ten (10) days of any assignment of this Agreement by
Licensee, and Licensee shall pay PHS, as an additional royalty, twenty thousand U.S. dollars ($20,000 U.S.)
for an assignment of this Agreement within thirty (30) days of such assignment.
	
     	
    14.08	 Licensee agrees in its use of any
PHS-supplied materials to comply with all applicable statutes, regulations, and guidelines, including PHS and
DHHS regulations and guidelines.  Licensee agrees not to use the materials for research involving human subjects
or clinical trials in the United States without complying with 21 CFR Part 50 and 45 CFR Part 46.  Licensee agrees not
to use the materials for research involving human subjects or clinical trials outside of the United States without notifying
PHS, in writing, of such research or trials and complying with the applicable regulations of the appropriate national
control authorities.  Written notification to PHS of research involving human subjects or clinical trials outside of
the United States shall be given no later than sixty (60) days prior to commencement of such research or trials.
	
     	
    14.09 	 Licensee acknowledges that it is subject
to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export
Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other
commodities.  The transfer of such items may require a license from the cognizant Agency of the U.S. Government or
written assurances by Licensee that it shall not export such items to certain foreign countries without prior approval of
such agency.  PHS neither represents that a license is or is not required or that, if required, it shall be
issued.
	
     	
    14.10	 Licensee agrees to mark the Licensed
Products or their packaging sold in the United States with all applicable U.S. patent numbers and similarly to indicate
“Patent Pending” status.  All Licensed Products manufactured in, shipped to, or sold in other countries
shall be marked in such a manner as to preserve PHS patent rights in such countries.
	
     	
    14.11 	By entering into this Agreement,
PHS does not directly or indirectly endorse any product or service provided, or to be provided, by Licensee whether
directly or indirectly related to this Agreement.  Licensee shall not state or imply that this Agreement
is an endorsement by the Government, PHS, any other Government organizational unit, or any Government
employee.  Additionally, Licensee shall not use the names of NIH, CDC, PHS, or DHHS or the
Government or their employees in any advertising, promotional, or sales literature without the prior written consent of
PHS.

	
     	
    14.12	The Parties agree to attempt to settle
amicably any controversy or claim arising under this Agreement or a breach of this Agreement, except for appeals of
modifications or termination decisions provided for in Article 13.  Licensee agrees first to appeal any such unsettled
claims or controversies to the designated PHS official, or designee, whose decision shall be considered the final agency
decision.  Thereafter, Licensee may exercise any administrative or judicial remedies that may be available.
	
     	
    14.13	Nothing relating to the grant of a license, nor
the grant itself, shall be construed to confer upon any person any immunity from or defenses under the antitrust laws or from a
charge of patent misuse, and the acquisition and use of rights pursuant to 37 CFR Part 404 shall not be immunized from the
operation of state or Federal law by reason of the source of the grant.
	
     	
    14.14 	Paragraphs 4.03, 8.01, 9.05-9.07, 12.01-12.05,
13.08, 13.09, and 14.12 of this Agreement shall survive termination of this Agreement.
	
     	
    14.15	Procept agrees that subsequent to market
approval by the Food and Drug Administration (FDA), to make reasonable quantities of Licensed Product(s) or materials
produced through the use of Licensed Process(es) available on a compassionate use basis, to patients, either through the
patient’s physicians) and/or the medical center treating the patient; and Procept further agrees, after their First
Commercial Sale, and to develop written educational materials (e.g., brochures, advertisements, etc.) directed to patients and
physicians detailing the Licensed Product(s) and/or medical aspects of using 06-Benzylguanine and/or its derivatives as a
therapeutic modality for the treatment of human cancers.

 

SIGNATURES BEGIN ON NEXT PAGE

  

 

 

PHS PATENT LICENSE AGREEMENT-EXCLUSIVE

SIGNATURE PAGE

For PHS:

/s/ Jack Spiegel, Ph.D.                                                 
                  2/2/02

  Jack Spiegel, Ph.D.                                                                              
  Date

  Director, Division of Technology Development and Transfer

  Office of Technology Transfer

  National Institutes of Health

Mailing Address for Notices:

  Office of Technology Transfer

  National Institutes of Health

  6011 Executive Boulevard, Suite 325

  Rockville, Maryland 20852-3804 U.S.A.

For Licensee (Upon, information and belief, the undersigned expressly certifies or
affirms that the contents of any statements of Licensee made or referred to in this document are truthful and
accurate.):

by:          Procept, Inc.

/s/ Salvatore A. Bucci                                                  
                  2/2/02

  Salvatore A.  Bucci                                                                             
  Date

  President and Chief Executive Officer

Official and Mailing Address for Notices:

369 Lexington Avenue, 10th Floor

  New York, NY 10017

  

  Any false or misleading statements made, presented, or submitted to the Government,
  including any relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject
  to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C.
  §1001 (criminal liability including fines) and/or imprisonment).Release Agreement

Exhibit 10.35

RELEASE AGREEMENT

               
This Agreement (this "Release Agreement") dated as of February 28, 2002 is entered into by and among Procept,
Inc. (formerly Pacific Pharmaceuticals, Inc.) ("Procept"), AOI Pharmaceuticals, Inc. (a subsidiary of
Access Oncology, Inc.) ("AOIP") and the United States Public Health Services ("PHS")
(Procept, AOIP and PHS, collectively, the "Parties").

                WHEREAS, The Penn State Research Foundation ("Foundation"), the University of Chicago ("UC") and
PHS are owners of certain patent rights associated with 06-Benzylguanine and/or its derivatives;

                WHEREAS, Foundation executed the following interinstitutional agreements with PHS:  L-094-91/0, executed May 20, 1997
(attached as Exhibit A); and with UC (Arch Foundation) executed (May 16, 1997) (attached as Exhibit B) whereby UC and
the Foundation received full power and authority to enter into a license agreement with Procept on or about February
6, 1998 (such license agreement, the "License Agreement" attached as Exhibit C), pursuant to which
Procept received an exclusive worldwide license to certain Patent Rights (as defined therein);

                WHEREAS, UC under an agreement with its affiliated corporation, ARCH Development Corporation has the right to license the
Licensed Patents and other intellectual property owned by ARCH;

                WHEREAS, Procept has sub-licensed certain of its interests, rights and obligations under the License Agreement to
AOIP pursuant to a sublicense agreement entered into by and between Procept and AOIP on or about October 13,
2000 (such sublicense agreement, the "Sublicense Agreement" attached as Appendix D);

                WHEREAS, UC, Foundation and the PHS have agreed to enter into the following interinstitutional agreements
("Interinstitutional Agreements"):  L-086-02/0, executed January 30, 2002; and L-067-02/0, executed January
29, 2002, copies of which are attached hereto as Exhibits E and F and pursuant to which PHS has exclusive licensing rights
associated with the Patent Rights;

                WHEREAS, Procept and PHS have executed a revised license agreement dated February 28, 2002, L-068-02/0 ("Revised
License Agreement"), to which this Release Agreement is attached regarding the Patent Rights licensed to
PHS which Revised License Agreement shall supercede and terminate the terms and conditions of the License
Agreement;

                WHEREAS, all of the Parties acknowledge that they will each derive substantial benefit from the Revised License Agreement,
the Sublicense Agreement and AOIP’s development efforts thereunder;

                NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

	 PHS
hereby irrevocably and absolutely releases and forever discharges bath Procept and AOIP, as well as their affiliates,
and their respective successors, predecessors, assigns, beneficiaries, executors, trustees, administrators, subrogees, agents,
representatives, employees, officers, directors, shareholders, partners, parent corporations, subsidiaries and affiliates
(collectively, "Released Parties"), of and from any and all claims, demands, obligations, debts, actions, and
causes of action of every nature, character, and description, known or unknown, pursuant to, arising out of, or related to the
License Agreement, which PHS now owns or holds, or has at any time heretofore owned or held, or may at any time own
or hold against the Released Parties, arising prior to and including the date of this Agreement.

	

In the event
the Revised License Agreement is terminated owing to a breach by Procept (as determined by a court of competent
jurisdiction or specific reference in a settlement of litigation) and AOIP is in good standing under the Sublicense
Agreement, PHS will grant a license directly to AOIP on substantially similar terms and conditions as those
contained in the Revised License Agreement (such newly granted license, the "New AOIP License").  It
is understood and agreed that unless and until such New AOIP License is executed, AOIP shall maintain its exclusive
Sublicense to the Patent Rights (as defined in the Sublicense Agreement) in accordance with the Sublicense
Agreement.  It is further understood and agreed that the Sublicense Agreement shall terminate upon execution of the
New AOIP License.  It is further understood and agreed to by PHS and AOIP that the royalty consideration
to be paid to PHS under the terms and conditions of the New AOIP License shall be the same as those terms contained
in Appendix C of the Revised License Agreement.

  
	

The
construction, validity, performance, and effect of this Agreement shall be governed by Federal law as applied by the Federal
courts in the District of Columbia.

  
	

 This
Agreement may be signed in one or more counterparts, each of which is to be considered an original, and taken together as
one and the same document.

  

[the rest of this
page is intentionally left blank]

 

 

 

- 2 -

                IN WITNESS WHEREOF, the Parties acknowledge by the signatures below of their authorized
representatives that they have read this Agreement and understand and agree to be bound by its terms and conditions.

 

	PROCEPT,
    INC.

    369 Lexington Avenue 

    10th Floor

    New York, New York 10017 

By:         
                                                                

Name:    
                                                               
 

Title:      
                                                                

     
	AOI PHARMACEUTICALS, INC.

    An Access Oncology Company

    750 Lexington Avenue

New York, New York 10022By:         
                                                                

Name:    
                                                               
 

Title:      
                                                                

     

	 	 
	UNITED STATES PUBLIC HEALTH SERVICE 

By:         
                                                               

Name:    
                                                               

Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]